Hyderabad-based Virupaksha Organics, Sigachi Industries expand operations in AP ₹1,225 -crore investment in Orvakal pharma hub to generate over 1,500 jobs

Andhra Pradesh is rapidly strengthening its position as a preferred destination for pharmaceutical manufacturing, with Hyderabad-based Virupaksha Organics Limited and Sigachi Industries Limited expanding their operations in Orvakal in Kurnool district.

The project envisages an investment of ₹1,225 crore and has the potential to create around 1,500 direct jobs, besides substantial indirect employment across logistics, utilities and ancillary services.

The expansions underscore the growing importance of Orvakal as an emerging pharma hub, supported by world-class industrial infrastructure and its strategic proximity to Hyderabad. Virupaksha Organics Limited has received approval for allotment of over 100 acres in the IP Guttapadu Cluster at the Orvakal Node for establishing a manufacturing facility for Active Pharmaceutical Ingredients (APIs) and organic chemicals.

While advocating promoting North Andhra as a mega pharma cluster as part of Visakhapatnam Economic Region, the government also wants to encourage various industries including investments in various regions without confining it to one area or region.

Orvakal’s rapid rise as a pharmaceutical cluster is being driven by its close proximity to Hyderabad, excellent road connectivity, availability of large, contiguous industrial land parcels and plug-and-play infrastructure developed by the Andhra Pradesh Industrial Infrastructure Corporation (APIIC). These advantages are prompting pharmaceutical companies to expand capacities in Andhra Pradesh while remaining closely linked to Hyderabad’s established life sciences ecosystem.

Virupaksha Organics Limited is a research-driven pharmaceutical company engaged in the manufacture of APIs and intermediates for both regulated and semi-regulated global markets. The company is known for its strong capabilities in process chemistry, quality compliance and export-oriented manufacturing, serving leading pharmaceutical players across geographies. On the other hand, Sigachi Industries Limited, headquartered in Hyderabad, is a leading manufacturer of pharmaceutical excipients, particularly microcrystalline cellulose (MCC), with applications across pharmaceuticals, food and nutraceuticals. With customers spanning India, Europe, the United States and other international markets, Sigachi has steadily expanded its manufacturing base to meet rising global demand.

The expansion plans of Virupaksha Organics and Sigachi Industries were formalised through MoUs signed at the CII Partnership Summit in Visakhapatnam, reflecting Andhra Pradesh’s proactive investment promotion efforts and its commitment to providing speed, certainty and scale to investors.

With multiple pharmaceutical and allied manufacturing projects now converging at Orvakal, Kurnool district is fast emerging as a key pharmaceutical manufacturing destination in South India, reinforcing Andhra Pradesh’s position as a competitive, industry-friendly state for life sciences investments.